Background. The new immunosuppressive drugs control acute rejection better, and have potentially short-term economic advantages. However, their long-term cost-effectiveness must still be determined. The Spanish study of chronic transplant nephropathy provides data that facilitates the assessment of the economic importance of maintenance immunosuppression (MI). Methods. We determined the frequency of use of the different MI drugs and their combinations in three renal transplantation cohorts performed in 1990, 1994 and 1998 (total: 3279), and their evolution over time. Based on the real costs found in a medium-sized service in our country at the end of 2000, the mean annual costs of MI drugs were calculated. We performed a multivariate analysis of graft survival in the 1998 cohort.
Introduction
The availability of new immunosuppressive drugs has led to an unquestionable advance in the control of acute rejection. The resulting savings in expenses due to hospitalization and treatment of acute rejection episodes make them also advantageous from an economic point of view, at least during the first post-renal transplantation (RT) year [1] [2] [3] [4] [5] [6] . However, their impact in terms of cost-effectiveness in the long term has yet to be determined [5] [6] [7] . Although the Spanish study of chronic allograft nephropathy has not been designed to perform economic analyses, it provides data that make it possible to assess the economic importance of these new immunosuppressive drugs.
Methodology
The data collection and processing methodology is described in detail elsewhere in this issue. The study did not record data on the drug doses, so it has not been possible to establish the real cost of maintenance immunosuppression (MI) medication. Thus, our analysis has focused on the rate of use of the different drugs and their combinations in the three cohorts of transplants studied (grafts performed in 1990, 1994 and 1998) and their evolution over time.
To obtain an approximate estimate of the MI cost, we resorted to the real costs found in a medium-sized service in our country at the end of 2000 [8] . Table 1 shows the mean values of doses, drug trough levels and annual cost for the main maintenance regimens that were found in patients with more than 1 year of post-transplantation evolution. In this study, although relatively insignificant, the annual cost included that of steroids (E50) and azathioprine (AZA) (E123).
These mean annual costs were multiplied by the number of patients treated with each regimen and the mean cost was obtained for the cohorts at the end of each year of post-transplantation. Use of other combinations of drugs (including sirolimus) was very limited, so they were not taken into account in the calculation of the mean costs. In a second step, the mean cost of each year was adjusted to the variation of the drug prices and purchasing value of the currency in the period 1990-2000. These two series of data were obtained from the manufacturing laboratories and from the publications of the National Institute of Statistics in Spain.
Statistics
Comparisons were performed with the Wilcoxon test, variance analysis, chi-square or Fisher tests. When appropriate, graft survival was studied by Kaplan-Meier curves and Cox's proportional hazards method, in a stepwise forward analysis, with the immunosuppressive treatment as a qualitative endpoint with four categories, corresponding to the four regimens used [with the regimen of cyclosporine (CsA) with or without AZA as reference]. Classification was made according to the treatment at 1 year, without considering later changes; i.e. an intention-to-treat analysis. We performed a first analysis of all the patients as a whole at 10 years, with correction for centre and year of transplant. In a second step, only the 1998 cases were considered: all the covariates that were statistically significant in the multivariate analysis of the three cohorts as a whole were introduced, adding the immunosuppressive treatment as one more covariate.
Results

Treatments used (Table 2)
In 1990 and 1994, CsA (with or without AZA and steroids) was used almost exclusively as the initial MI drug. In 1998, the predominant anti-calcineurin continued to be CsA [used in 76.2% of the patients vs tacrolimus (TAC) usage in 20% of patients], although Calculations were based on those patients specifying the immunosuppressive regimen. it was used alone or with AZA in only 22.1% of patients. A total of 65.2% of the patients received mycophenolate mofetil (MMF): 54.1% associated with CsA (the predominant regimen) and 11.1% with TAC.
In the 1990 and 1994 cohorts, no changes in the treatment model until 1996 were noted (sixth year for 1990 and second year for 1994), the year in which the commercial introduction of the new drugs occurred. Afterwards, the proportion of cases with TAC and, above all, with MMF began to increase. This tendency is significantly greater in the 1994 cohort; at the end of the study 7.7% of the patients had been switched to TAC and 16.9% to MMF, vs 4.4 and 12.2% of the 1990 survivors. As a whole, including the cases that failed or died, 24.5% of the 1994 patients had changed treatment vs 16.9% of those in 1990. In 1998, the distribution of the regimens changed relatively less between the beginning and the end of the study (second year for this cohort). Only an increase in the use of TAC as a calcineurin inhibitor was noted (from an initial 20.0% TAC vs 76.2% CsA usage to 24.4% TAC and 71.3% CsA usage in the second year).
Cost of MI
Using the prices of the year 2000, the mean cost of the MI in the first year in 1998 (E5380) was almost twice that in 1994 (E2902) and 1990 (E2855). In the 1990 and 1994 cohorts, the mean cost remained stable and was very similar between both until 1996 ( Figure 1) . Afterwards, it increased continuously in both cohorts, although more rapidly in the cohort of 1994 (from E2902 to E3622 at the end of the study) than in 1990 cohort (from E2855 to E3349). At the end of the study, the mean cost continued to be significantly lower in both groups than in the 1998 cohort. In the latter cohort, the mean cost remained completely stable between the initial time and the second year.
The total cost of MI generated by the group of the surviving patients in each cohort in the first year and at the end of the study is shown in Figure 2 (at year 2000 prices). The great increase in 1998 not only reflects the difference in the mean cost but also in the size of the cohorts, derived from the important increase in transplantation activity recorded in our country during the 1990s.
During these years, the currency lost more than 40% of its purchasing power, while the drug prices remained stable at first and then, after 1997, experienced a considerable reduction. Once adjusted for these two phenomena, the evolution of the mean cost offers a completely different picture (Figure 3 ). In euros, for the year 2000, the economic burden tended to lower at the end for the three groups, especially for the most recent cohort.
Collateral aspects related with cost
The four main regimens that were used showed significant differences in certain aspects that could have possible repercussions on the cost of RT. The comparison was limited to the 1998 cohort to avoid biases related to the baseline characteristics of the patients or changes in medical practice regarding management of cardiovascular risk factors. The following points can For the 1998 cases, the multivariate analysis showed the following prognostic factors of organ survival: donor age, occurrence of acute rejection in the first year, renal function and proteinuria at the third month and their increases between the third month and the first year. In this model, the MI did not appear to be a statistically significant factor.
Discussion
The present study has some clear methodological limitations. As it lacks dosing data, the cost calculation had to be based on measurements carried out in only one of the participating centres and at only one point in time. A great uncertainty about the representativeness of the sample used to establish the dosing and combined costs must be recognized: there is probably marked variability in the treatment habits between centres over the period considered. For example, in this local study [8] , the rate of steroid-free patients was much greater on average than in the other centres; this can explain the higher dose maintenance and levels of the other drugs, with the consequent increase in cost in the reference centre. Thus, only an approximate character of the cost calculation could be made; on the other hand, this analysis may be useful as an estimation of the order of magnitude of the changes experienced.
The incorporation of the new immunosuppressive drugs, TAC and MMF, in the medical practice of our country occurred rapidly after 1996. Consequently, a strong increase has been generated in the MI costs of the most recently transplanted patients. At the same time, a growing number of older patients are receiving these drugs, probably most frequently as a resort against the development of chronic allograft nephropathy. The economic impact of the new generation of drugs is thus very important in absolute terms. However, this impact is lessened by the stability or decrease of the immunosuppressive drug prices despite the loss of purchasing value of the currency. RT is a procedure that continually gains efficiency: so has it been demonstrated that the years of life gained by the money invested in RT increase much faster than for other maintenance treatments of renal failure, such as haemodialysis [9] .
The extra cost of the new drugs (TAC, MMF, anti-IL2R antibodies) seems to be perfectly justified during the first post-RT year, because of the decrease of the costs associated with acute rejection [1] [2] [3] [4] [5] [6] . However, this result is much less clear in the long term [5, 6] . The problem lies not only in the lack of a definitive demonstration but above all, by the lack of an exact Fig. 3 . Evolution of mean cost, corrected for evolution of prices and purchasing value of the currency.
quantification of the hypothetical improvement of long-term graft survival with the new MI. With regard to our study, we have at present not been able to demonstrate a significant improvement in kidney survival after the first year. This can undoubtedly be due to an insufficient sample size and follow-up duration. In fact, there are already solid data from some clinical trials [10] and from large registries [11] that MMF is associated with a prolongation of the mean graft life. The evidence is much weaker for TAC [12, 13] . The assessment of a cost-benefit of the new regimens is thus still pending and new and more extensive studies are needed.
In fact, the essential question must still be resolved: what is the ideal MI regimen? It cannot be denied that the final solution is to lessen MI, instead of adding new components. For example, reducing [14] or eliminating calcineurin inhibitors [15] , withdrawing MMF [16] or even drastically decreasing MI [17] should be attempted. In this case, the cost-benefit would be increased on two components: longer life of the healthier transplanted patients and less drug expenses. Initially, the position of our centres was very conservative: in the 1998 patients and during the first 2 years, the tendency was to maintain the MI prescribed at the beginning. In other words, the above-mentioned possibilities of simplifying MI were not been put into practice until then.
An integral study of RT cost should consider very different and varied aspects of MI. Thus, prolonged use of steroids gives rise to significant costs due to its associated side effects such as diabetes, osteoporosis, cataracts, etc. [18] . The new MI regimens have a high potential for withdrawal of steroids [19] . This study only shows a very modest application of this strategy: complete withdrawal of steroids in the second year occurred only in one-sixth of the patients in the best of cases. On the other hand, the use of the more expensive calcineurin inhibitor, TAC, seems to be associated with a lower need for antihypertensive agents and lipidlowering drugs. The cost of these drugs is much lower than that of MI, but not negligible. Thus, in the study that has been used as a reference, the mean cost of antihypertensive agents per patient-year increased to E257; that of lipid-lowering drugs varied between E107 and E1594 per year, with a significant difference in favour of TAC (lower cost) compared with CsA. A better cardiovascular risk profile related with the MI regimen can have two beneficial effects for the cost-benefit relationship: it directly decreases the drug and comorbidity costs, and it increases patient and graft survival.
Unlike other solid organ transplantations, the alternative to RT is not a tragic interruption of an individual's health care expenses, but rather a very expensive procedure, that of dialysis [20] . In 2000, the annual cost of haemodialysis in the most frequently provided form (in a medium-sized centre in Andalucia, in which the MI costs were calculated) was E20 636. Reliable data regarding transportation costs, also covered by the public health system, could not be obtained, but it was estimated that they were not less than 10-15% of the above figure. Cost for erythropoietin of E3200 per patient and year (the authors' data) must be added to this. In contrast, the cost of human resources for the outpatient follow-up in the same reference service was <E350 per patient and year (the authors' data). That is, the basic cost of the alternative therapy to transplantation, i.e. haemodialysis, is several times higher than that of any of the new regimens [21] . Due to the savings in dialysis costs, an increase of a few years in the mean life of the graft would not only provide an obvious improvement in the quality of life of the patients, but would compensate and even exceed the increases in costs derived from the new regimens. In any event, it is clear that because of its great economic importance and its clinical benefit further efforts should be made in the search for the ideal MI.
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